Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

Daniel Y. Joh(Duke University), Ashutosh Chilkoti(Duke University), Amy B. Cheng(Duke University), Suzanne E. Wardell(Duke University), Jayanta Bhattacharyya(Indian Institute of Technology Delhi), Kris C. Wood(Duke University), Angus Hucknall(Duke University), Terry Hyslop(Thomas Jefferson University), Jacob T. Heggestad(Duke University), Sachiko M. Oshima(Duke University), E. Shelley Hwang(Duke University), Qingshan Wei(North Carolina State University), Kyle C. Strickland(LabCorp (United States)), Grace R. Anderson(Duke University), Shengwei Zhang(North Carolina State University), Jason Liu(University of California, Los Angeles), Allison Hall(Duke Medical Center), Simone A. Wall(Duke University), Faris M. Albarghouthi(Duke University)
npj Breast Cancer
September 17, 2021
10.1038/s41523-021-00335-4
Cited by 3

Related Papers

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
|Oncotarget|2016|616
In Pursuit of Zero: Polymer Brushes that Resist the Adsorption of Proteins
|Advanced Materials|2009|549
Tunable Drug Release from Hydrolytically Degradable Layer-by-Layer Thin Films
|Langmuir|2005|287